The BAFF receptor BR3 plays key roles in B-cell activation, maturation, and survival whereas the function of BR3 on T lymphocytes is less well characterized. Previous reports have demonstrated that BR3 costimulates human T-cell activation in vitro in the presence of high nonphysiological levels of plate-bound BAFF. Here, relying on the soluble and membrane-bound BAFF expressed by T cells themselves, we investigated the function of BR3 on activated primary CD4 + and CD8 + T lymphocytes using a BR3-specific neutralization antibody and shRNA gene down-modulation. Interestingly, the anti-BR3 blocking antibody resulted in significant augmentation of CD25 and IFN-γ expression by both subsets, as did shRNA-mediated down-modulation of BR3. In addition, granzyme B expression was substantially elevated in anti-BR3-treated and BR3-silenced T cells. Anti-BR3 blockade increased the expression of CD25 on cytolytic CRTAM + T cells. Importantly, anti-BR3 significantly enhanced redirected killing of P-815 cells by both CD4
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The BAFF receptor BR3 plays key roles in B-cell activation, maturation, and survival whereas the function of BR3 on T lymphocytes is less well characterized. Previous reports have demonstrated that BR3 costimulates human T-cell activation in vitro in the presence of high nonphysiological levels of plate-bound BAFF. Here, relying on the soluble and membrane-bound BAFF expressed by T cells themselves, we investigated the function of BR3 on activated primary CD4 + and CD8 + T lymphocytes using a BR3-specific neutralization antibody and shRNA gene down-modulation. Interestingly, the anti-BR3 blocking antibody resulted in significant augmentation of CD25 and IFN-γ expression by both subsets, as did shRNA-mediated down-modulation of BR3. In addition, granzyme B expression was substantially elevated in anti-BR3-treated and BR3-silenced T cells. Anti-BR3 blockade increased the expression of CD25 on cytolytic CRTAM + T cells. Importantly, anti-BR3 significantly enhanced redirected killing of P-815 cells by both CD4
+ and CD8 + cytotoxic T cells [cytotoxic T lymphocytes (CTLs)]. Furthermore, anti-BR3-augmented CD4 + T-cell-mediated killing of class II + melanoma cell line A375 and cervical cancer cell line HeLa in vitro, increasing the level of granzyme B activity as measured by PARP-1 cleavage and active caspase 3. Together, our data indicate that BR3 neutralization increases the activation and cytolytic function of CD4 + and CD8 + cytotoxic T lymphocytes. Our findings provide a novel strategy for ex vivo T-cell activation applicable to T-cell immunotherapy platforms such as TIL or CAR-T cell therapeutics.
Key Words: BAFF-R, BR3, BAFF, cytotoxic T lymphocytes, T-cell activation (J Immunother 2018;41:213-223) B R3 (BAFF-R) is a member of the TNF receptor family known for its essential role in B-lymphocyte activation, maturation, and survival. BAFF (THANK, TALL-1) is the sole ligand for BR3, and together with its sister ligand APRIL binds TNF receptors TACI and BCMA. [1] [2] [3] [4] Increases in BAFF expression perturb the homeostatic balance of B lymphocytes and are strongly associated with autoimmunity and antibody-mediated transplant rejection. 2, [5] [6] [7] In addition, high BAFF levels in bone marrow have been linked to B-lymphocytic malignancies. 8 Compared with the extensive studies of the function of BR3 on B cells, its function(s) on T cells are less well defined. It has been demonstrated that human CD4 + and CD8 + T cells express BR3 in resting and activated states. 4, [9] [10] [11] [12] In several reports, human CD4
+ T H cells stimulated with anti-CD3 in the presence of high nonphysiological concentrations of plate-bound BAFF displayed augmented activation and proliferation. [11] [12] [13] However, in the presence of more physiological levels of BAFF, the role of BR3 in human T-cell activation remains unclear. In addition, there are no detailed reports of the actual function of BR3 on human cytotoxic T lymphocytes (CTLs). Many receptors within the TNF receptor family such as 4-1BB (CD137), OX40 (CD134), and GITR costimulate CD4 + and CD8 + T-cell activation. 14, 15 These, along with other TNF-R family members, have been shown to play a significant role in augmenting T-cell activation for cancer immunotherapies. For example, the signaling domain of 4-1BB is included in many CAR-T-cell constructs to enhance the activation of transfected T cells while GITR and OX40-specific agonists have been applied in vivo as costimulatory agents. [14] [15] [16] [17] [18] Curiously, studies of receptors within the BAFF/APRIL system have not yet been described in the context of T-cell coactivation for cancer immunotherapy.
In this study we investigated the role of BR3 in the activation of human effector T cells. In our system, activated T cells were the sole source of the BAFF ligand and as such BAFF levels were at low (pg/mL) concentrations. We worked with one of the few commercially available human BR3 blocking antibodies to determine the degree to which BR3 was specifically involved in T-cell costimulation in vitro. In addition, we down-modulated BR3 in primary human T cells via shRNA gene silencing. Results of both methodologies suggest that BR3 inhibition increases the activation of both CD4 + and CD8 + CTLs. Importantly, anti-BR3-mediated neutralization augments the cytolytic function of CD4 + CTLs by promoting the apoptosis of tumor cell lines in vitro.
MATERIALS AND METHODS

Cell Culture and Purification
Primary human T cells were obtained from leukopheresis products purchased from AllCells, LLC (Alameda, CA) or Key Biologics, LLC (Memphis, TN). Upon arrival, PBLs were isolated via ficoll separation and viably frozen. 19 Thawed PBLs were subjected to T-cell subset purification by magnetic bead sorting.
For purification, CD4-specific or CD8-specific beads from Miltenyi Biotec Inc. (San Diego, CA) were used according to manufacturer protocol. An AutoMacs sorter (Miltenyi Biotec) was used for bead selection. CD4 and CD8 T-cell populations were typically 90%-95% pure. All T-cell assays were performed in complete Roswell Park Memorial Institute (RPMI) containing 10% fetal bovine serum (FBS), glutamine, HEPES, Na-pyruvate, NEAA, and Pen/Strep.
The human melanoma line A375 and cervical cancer cell line HeLa were purchased from ATCC (Manassas, VA).
A375 and HeLa cells were expanded in complete RPMI containing 10% FBS. P-815 mastocytoma cells were also purchased from ATCC and grown in complete RPMI containing 10% FBS. 
Flow Cytometry
Anti-BR3 Neutralization Assays
BAFF receptor blocking antibodies anti-BR3 (cat# AF1162), anti-TACI (cat# AF174), and anti-BCMA (cat# AF193), were purchased from RnD Systems Inc. All 3 are goat polyclonal antibodies. The goat IgG isotype control (cat# AB-108-C) was also purchased from RnD Systems Inc. All were received as lyophilized products and resuspended in PBS at the recommended concentrations, aliquoted, and frozen according to manufacturer's instructions.
For blocking assays, CD4 and CD8 T-cell subsets were bead-selected as described previously and suspended in complete RPMI (previously shown) at 1×10e6/mL. Cells were preincubated with each neutralizing antibody or normal goat IgG control (cat# AB-108-C) at 10 µg/mL for 30 minutes at 25°C. Next, 2×10e5 cells/well were added to 96-well flat bottom tissue culture treated plates; 4×10e5/mL were added to 48-well plates. Plates were precoated with 1 µg/mL anti-CD3ε (clone UCHT1, RnD Systems Inc.) and 0.2 µg/mL anti-CD28 (clone 37407, RnD Systems Inc.) at 25°C overnight with 2 subsequent PBS washes and a 30 minute block with undiluted FBS. T cells were activated and incubated for 21-24 hours in a 37°C incubator at 5% CO 2 after which cells were gently harvested and supernatants collected and stored at −20°C for future enzyme-linked immunosorbent assay (ELISA) analysis.
BR3 shRNA Down-modulation
Three shRNA plasmid constructs specific for human BAFF-R were purchased from Dharmacon Inc. including the GIPZ shRNA control plasmid. In total, 1-2 µg of each plasmid was introduced into 4-7×10e6 CD4 or CD8 T cells using Amaxa-based nucleofection. Amaxa kits specific for human T-cell transfection were purchased from Lonza Inc. Program V-24 was used for electroporation according to manufacturer's instructions after which cells were rested for 5-6 hours in 12-well plates containing prewarmed complete RPMI. Cells were then gently harvested and added at 1×10e6 cells/well to 12-well plates precoated with anti-CD3/anti-CD28 (1 and 0.2 µg/mL, respectively, as shown previously). Transfected T cells were rested or activated for 21-24 hours. Cells were then harvested and analyzed for BR3, CD25, granzyme B, and IFN-γ as described previously. Sequences for shRNA are as follows: (p685) 334685 mature antisense sequence: GCGGCTGCAGC GCCGTCCT, (p835) 404835 antisense sequence: GGTCTG TAGTGTCTGTGCT.
Cytotoxicity Assays
Redirected Cytotoxicity Assay
CD4
+ and CD8 + cells from donor 1 were purified and suspended in complete RPMI media containing 3% FBS. P-815 mastocytoma cells were also suspended in complete RPMI with 3% FBS. Anti-huCD3ε (clone UCHT1, RnD Systems Inc.) was added at 10 µg/mL to P-815 cells. T cells were incubated with goat IgG or anti-BR3 at 20 µg/mL for 30 minutes before coculture. In total, 100,000 T cells were cocultured with P-815 cells at a 20:1 ratio at 100 µl/well in quadruplicate wells. The final concentration of anti-CD3 was 5 µg/mL. The final concentration of IgG/anti-BR3 was 10 µg/ mL. The P-815 cells alone served as a background lysis control while SDS was added to P-815 cells for the total lysis control. T cells without P-815 cells also served as controls. After 4 hours of incubation, supernatants were analyzed for levels of Lactose dehydrogenase using the Cyto96 Kit (Promega Corporation Inc.) according to manufacturer's instructions. Absorbance was read after a 30 minute incubation period with substrate. Percent lysis was calculated according to manufacturer's protocol. Data represent 5 separate experiments.
Cleaved PARP/Caspase 3 Assay
Granzyme B-mediated killing was analyzed by flow cytometry as previously described. [20] [21] [22] Briefly, CD4 + T cells were purified from donors 1 and 2 via bead selection as shown previously. Tumor cell lines were labeled with CT-Red (Invitrogen Inc.) according to manufacturer's instructions. In total, 4×10e5 CD4 + cells at 1×10e6/mL were incubated with 10 µg/mL goat IgG or anti-BR3 for 30 minutes before adding them to wells of a 48-well plate precoated with anti-CD3/anti-CD28 as shown previously. Labeled tumor cells were then added at a 25:1, T cell: tumor cell ratio for 18 hours. Cells were harvested, and intracellular flow cytometry was performed using fixation and permeabilization buffers from RnD Systems Inc. Cells were stained with anti-cleaved PARP PE (BD Biosciences Inc.) and anti-active caspase 3 FITC, gating on the CT-RED + tumor cells. Cells were analyzed on C6 and FlowJo software for percent cleaved PARP and active caspase 3 positive cells.
Semiquantitative Polymerase Chain Reaction (PCR)
RNA was isolated from activated T-cell subsets treated with or without anti-BR3 for 21-24 hours. Total mRNA was isolated using an RNA Easy kit (Qiagen Inc.). cDNA was generated using the Verso cDNA Synthesis kit (Thermo Dynamics Inc.). All primers used to amplify GAPDH, CD25, BAFF, BCMA, BR3, CD69, IFN-γ, IL-2, granzyme B, and perforin were Quantitect Primers from Qiagen Inc. A SYBR Green-based PCR kit (Applied Biosystems Inc.) was used to amplify cDNA on a StepOnePlus thermocycler according to previously established protocols.
ELISA
Tissue culture supernatants were harvested after 21-24 hours from assays noted previously and frozen at −20°C. Human IFN-γ concentrations in culture supernatants were measured using an ELISA kit from Thermo-Pierce Inc. Human granzyme B and BAFF were measured using ELISA (DuoSet) kits from RnD Systems Inc. Absorbance was read at 450 nm on an Epoch microplate reader from BioTek Inc.
Statistical Analysis
Statistics were performed using GraphPad Prism version 6.0 for Windows OS (GraphPad Software, San Diego, CA). We reported data as mean ± SEM. Two-tailed paired t tests were performed when comparing 2 groups.
RESULTS
BR3 and BAFF Expression by Resting and Activated T cells
We began our analysis by examining BR3, BCMA, and TACI expression on T cells isolated from 5 healthy blood donors. Bead-purified CD4 + and CD8 + cells were rested or activated using plate-bound anti-CD3 and anti-CD28 antibodies for 24 hours. BR3 was expressed on both resting and activated T-cell subsets, with significant increases on stimulated T cells (Fig. 1A) . BCMA was expressed on both resting and activated T-cell subsets, albeit lower than BR3 on activated T cells, averaging 6% ± 2% (representative overlays for CD8 + T cells, Fig. 1B ). Semiquantitative PCR of all 3 BAFF receptors revealed relatively equal mRNA expression of BR3 and BCMA in activated CD4 + and CD8 + T cells (Fig. 1B) , whereas TACI gene expression was not observed (data not shown). Cell surface BAFF was detected equally on T cells rested and activated for 24 hours (representative overlay, Fig. 1C ). Soluble BAFF was detected at 20 ± 10 pg/mL in activated T-cell supernatants but was undetectable for resting cells (data not shown).
CD25 is an established marker of T-cell activation and a seminal marker for CD4 + Tregs. 23, 24 In our system, 10%-40% of T cells expressed CD25 at 24 hours of activation. Less than 1% of resting CD4 + T cells were BR3 + CD25 + (Fig. 1D) . On average, 30%-50% of activated CD4 + BR3 + T cells and 20%-30% of activated CD8 + BR3 + cells expressed CD25 (see representative dot plot, Fig. 1D ).
Anti-BR3 Neutralization Increases CD25 Expression
We hypothesized that if BR3 costimulated human T lymphocytes, as has been suggested by other studies, [11] [12] [13] then BR3 neutralization should decrease T-cell activation and therefore CD25 expression. As BCMA was also expressed on human T cells, the specific function of BR3 could not be determined using BAFF competitors such as anti-Blys (Belimumab) or TACI-Fc (Atacicept). As such, we used a BR3 neutralization antibody, a goat polyclonal antibody from RnD Systems Inc. Goat IgG as well as anti-TACI and anti-BCMA goat polyclonal blocking antibodies (also from RnD Systems) served as controls. CD4 + and CD8 + T cells were preincubated with each neutralization antibody or goat IgG for 30 minutes before stimulating with plate-bound anti-CD3/anti-CD28. After 24 hours, CD25 expression was measured by flow cytometry and semiquantitative PCR. Flow analysis revealed that anti-BR3 blockade significantly increased the percentage of CD25 + cells (P < 0.05, Fig. 2A ) as well as the mean channel fluorescence (MCF) of CD25 (P < 0.05, Fig. 2B ) for both CD4 + and CD8 + subsets. The goat IgG control, anti-TACI, and anti-BCMA had no significant effect on CD25 expression. CD25 mRNA expression increased 1.5-6 fold for CD4 + cells, and 2-3 fold for CD8 + cells but only increases in CD25 expression of CD8 + cells were statistically significant (P < 0.05, Fig. 2C ). The MCF of CD69 as well as CD69 mRNA expression remained unchanged with BR3 blockade (data not shown) suggesting that BR3 neutralization increased selective components of T-cell activation.
BR3 Antibody Blockade Increases Expression of IFN-γ and Granzyme B
We next examined whether anti-BR3 had an effect on IFN-γ, a key cytokine expressed at the onset of T-cell activation and integral to cancer biology. 25, 26 As shown previously, purified T cells were incubated with each of the neutralization antibodies or IgG and then stimulated with anti-CD3/anti-CD28. Compared with the IgG control, anti-BR3 treatment increased IFN-γ concentrations 2-5 fold in culture supernatants, as measured by ELISA, and was statistically significant for both CD4 + and CD8 + T-cell subsets ( Fig. 3A , P < 0.001 and P < 0.01 for CD8 + than CD4 + cells, respectively). Anti-BCMA and anti-TACI did not increase IFN-γ expression. Semiquantitative PCR analysis comparing IFN-γ mRNA expression in IgG versus anti-BR3-treated T cells demonstrated 2-10 fold and 2-6 fold increases in anti-BR3-treated CD4 + and CD8 + cells, respectively (Fig. 3B) .
As BR3 blockade augmented CD8 + T-cell activation at 24 hours, we considered whether the expression of cytolytic factors was likewise enhanced. Semiquantitative PCR analysis of anti-BR3-treated T cells demonstrated increases in granzyme B expression compared with the IgG control, both for CD4 + and CD8 + subsets, whereas perforin mRNA levels were not changed (Fig. 3C) . ELISA analysis demonstrated that granzyme B levels in tissue culture supernatants increased significantly (2-10 fold) for both subsets (P < 0.05, Fig. 3D ).
Silencing of BR3 Gene Expression Increases Anti-CD3/Anti-CD28-mediated T-Cell Activation
To determine whether enhanced T-cell activation mediated by the anti-BR3 antibody was a result of BR3 neutralization or due to incidental antibody binding, we examined the effects of shRNA gene silencing of BR3 on stimulated T cells.
We tested 3 BR3-specific shRNA constructs as well as the control shRNA GIPZ plasmid (Dharmacon Inc.) in primary human T cells. Briefly, purified CD4 + and CD8 + T cells were transfected via nucleoporation (Amaxa Inc.), rested, and then rested further or activated by plate-bound anti-CD3/anti-CD28 (see section Materials and Methods). Nucleoporation dramatically decreased the viability of primary T cells and in our hands often resulted in 70%-80% cell death. As such, we used flow cytometry to analyze transfected/nucleoporated T cells, as we could easily gate out dead cells. Transfection efficiencies were measured by GFP positivity.
To varying degrees, all 3 BR3 shRNA constructs decreased BR3 expression in cells rested for 24 hours, as demonstrated by flow cytometry. However, 2 constructs, p835 and p685, consistently down-modulated BR3 compared with the pGIPZ control. CD25 was analyzed in CD4 + T cells since the greatest differences in CD25 expression with anti-BR3 were seen in CD4 + cells. CD4 + cells were also used for intracellular IFN-γ analysis, as they expressed higher levels of IFN-γ. For these experiments, purified cells were transfected, rested for 5 hours, and then activated with plate-bound anti-CD3/anti-CD28 for 21-24 hours.
As shown in Figure 4A , p685 significantly downmodulated the expression of BR3 in BR3 + CD4 + T cells compared with the pGIPZ control. In concert with BR3 reduction, both CD25 and IFN-γ were significantly increased (P = 0.03 and 0.02, respectively, Fig. 4A ). In addition, the percent IFN-γ + cells also increased with p685-mediated BR3 down-modulation (P = 0.02, Fig. 4A ).
We used CD8 + cells to determine whether granzyme B was influenced by BR3 down-modulation, as a greater percentage of CD8 + cells express granzyme B than CD4 + cells. As shown in Figure 4B , p835 significantly reduced the expression of BR3 in BR3 + CD8 + cells compared with the pGIPZ control. The expression of granzyme B increased in the p835 Br3-silenced CD8 + cells compared with the control shRNA (P = 0.02). These data support the hypothesis that BR3 inhibition increases anti-CD3/anti-CD28-mediated T-cell activation. Anti-BR3 Enhances the Cytolytic Function of CD4 + and CD8 + T cells
To assess whether anti-BR3 enhances the cytolytic function of CD4 + and CD8 + T cells, we performed a redirected cytolytic assay using murine mastocytoma P-815 cells as the tumor target. 29, 30 Here, anti-CD3 pulsed P-815 cells were cocultured with CD4 + or CD8 + T cells at a 20:1 ratio for 4 hours. Lactose dehydrogenase levels released from lysed target cells were then measured using an absorbance assay (Cytotox96, Promega Inc.). As shown in Figure 6A , both CD4 + and CD8 + cells displayed significant increases in target killing in the presence of anti-BR3 versus the IgG control.
To determine whether anti-BR3-treated CD4 + CTLs could enhance granzyme B-mediated killing of HLA class II + targets, we screened a series of HLA-DR + human tumor lines for direct killing via alloantigen recognition. Melanoma line A375, as well as the cervical carcinoma HeLa cell line, were cocultured with CD4
+ T cells at a 25:1 ratio for 18 hours, with or without anti-BR3. Apoptosis was then indirectly measured by intracellular levels of cleaved PARP-1 and active caspase 3, two proapoptotic substrates of granzyme B. [20] [21] [22] As shown in Figure 6B , both lines demonstrated significant increases in the percentage of c-PARP-1 + populations in the anti-BR3-treated cocultures, as much as 2-fold depending on the CD4 + T-cell donor. Active caspase 3 was similarly increased (data not shown). This suggests that 
DISCUSSION
In this report, we demonstrate that BR3 can limit anti-CD3/anti-CD28-mediated T-cell activation and cytotoxicity. Inhibiting BAFF binding to BR3 or down-modulating BR3 expression augments CD25, IFN-γ, and granzyme B expression. In addition, our results demonstrate that BR3 blockade increases CD25 expression on cytolytic CRTAM + CD4
+ and CD8 + T cells. Finally, neutralization with anti-BR3 enhances CTL killing of class II + tumor lines in vitro. We are cognizant of previous reports that show BAFF can costimulate TcR-mediated T-cell activation in vitro. [10] [11] [12] [13] Those reports which address human T-cell activation 11, 13 vary from ours in several distinct ways. First, plate-bound BAFF (4-10 µg/mL) was used in T-cell activation assays, whereas we relied on the membrane-bound and low pg/mL levels of soluble BAFF expressed by the activated T cells themselves. In addition, BR3 was designated as the BAFF receptor mediating T-cell coactivation based on the relatively low to nil expression of TACI and BCMA. 11, 13 In our analyses, we found notable expression of BCMA in activated human T cells, although like others we were unable to detect TACI expression. As such, it is possible that high concentrations of BAFF could (also) trigger BCMA to activate cells, as BCMA has a 100-fold lower affinity for BAFF compared with BR3. 31 Therefore, specific blockade of BR3 as well as its down-modulation was necessary to determine whether BR3 specifically augments human T-cell activation in vitro. In our experimental system, we demonstrate that BR3 can limit the activation of CTLs.
BR3, TACI, and BCMA are all TRAF-binding receptors which associate them with pro-inflammatory, not inhibitory, functions. 3, 32 However, the difference between BR3-mediated T-cell suppression and activation could depend upon low versus high BAFF levels, similar to the TNF death receptor CD95 where low concentrations of soluble CD95L can induce cell proliferation and not apoptosis. 33, 34 Another possibility lies in the fact that BR3 is unique among BAFF receptors in that it regulates PKC-δ 3,35 perhaps explaining its suppressive function. To this end, it has been demonstrated that PKC-δ increases lysosomal activity in CTLs. 36 Experiments are underway to determine whether disparate BAFF levels and/or PKC-δ signaling are linked to BR3-mediated CTL suppression.
It is not without precedent to suggest that BR3 may suppress CTL responses. For example, in a murine EAE model where T cells play a central role in the disease state, BAFF-R/BR3 deficiency led to increased disease severity. 37 Curiously, in clinical trials using anti-BAFF therapeutics for autoimmune diseases such as multiple sclerosis, there have been instances of increased disease severity 5 leading one to hypothesize that BAFF could be suppressing CTL activation in vivo. If such is the case, then elevated BAFF levels in tumor microenvironments, shown in several B-cell malignancies, 8 could be inhibitory to CTLs while supporting B-cell survival.
One potential application of BR3 neutralization could be for ex vivo T-lymphocyte activation in chimeric antigen and tumor infiltrating T-cell-based cancer immune therapies. [38] [39] [40] Currently, activation and expansion of CAR-Ts or TILs is implemented primarily by stimulating cells with anti-CD3 and anti-CD28 with subsequent IL-2/7/15-based expansion. [40] [41] [42] [43] Given our data that demonstrate an increase in expression of the high affinity IL-2 chain CD25 on CRTAM + T cells, we propose that addition of an anti-BR3 neutralization antibody could enhance the proliferation and expansion of CD4 + and CD8 + CTLs. In addition, our novel finding that CD4 + CTLs can be activated by anti-BR3 bode well for TIL immunotherapies where tumors express class II, providing a 'second arm' of CTL target antigen coverage.
